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ABSTRACT
Due to the rise of multidrug-resistant infections in humans, phage therapy is gaining renewed
attention in Western medicine. Despite the increasing number of publications focussed on the
isolation, characterization and in vitro performance of different phages, there is still a lack of con-
cise pre-clinical information to guide the application of phage therapy in clinical practice.
Nevertheless, over the last decade, efforts have been made to conduct more detailed studies of
the in vivo efficacy of phages. Here, we review the most relevant in vivo studies performed in
the last decade covering phage efficacy in both preclinical and clinical trials. We compare differ-
ent routes of administration, dosage effect and different animal models of distinct types of infec-
tions. Moreover, insights into case studies and results from clinical trials are presented.
Challenges and limitations of phage use as evidenced by the current state of research are also
discussed in order to improve both the trustworthiness and success of the implementation of
phage therapy.
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Multidrug-resistant (MDR) bacteria are recognized as
one of the most critical public health problems. The
Infectious Diseases Society of America recognized the
worldwide dissemination of antimicrobial resistance as
one of the greatest threats to human health (Spellberg
et al. 2011). Taking into account that MDR-related infec-
tions are responsible for a relatively high number of
hospital mortalities and long hospitalization periods,
the rise of antimicrobial resistance has a huge impact
on society and the economy (Vardakas et al. 2013).
Indeed, it is estimated that 48,000 people die yearly in
Europe and the USA as a consequence of MDR infec-
tions (Davies 2013; Executive Office of the President
President’s Council of Advisors on Science and
Technology 2014). The World Health Organisation
recently published a list of MDR priority pathogens,
encouraging both the scientific community and the
pharmaceutical industry to develop new antimicrobials
to combat these dangerous pathogens (World Health
Organization 2017).
Today, a century after their discovery, bacterio-
phages (phages) are proposed as a therapeutic solution
to combat MDR infections. Phages are viruses and, as
obligatory cell parasites, they only propagate on bacter-
ial hosts. Phages can either be strictly lytic or temperate
depending on their propagation strategies. During a
bacterial cell infection, a phage adsorbs to its host and
inserts its genetic material into the cell. Phages can fur-
ther follow one of two life cycles: lytic or lysogenic. All
phages can follow the lytic cycle, which ends up with
the death of the bacterial cell. In addition, some phages
can follow the lysogenic cycle in which the viral gen-
ome is integrated into the bacterial genome and is fur-
ther replicated along with bacterial cell division. Under
certain conditions, lysogenic phages can be induced to
follow a lytic cycle. Temperate phages are described to
be involved in horizontal gene transfer phenomena,
namely on the spread of virulence factors.
Consequently, this type of phage is not recommended
for phage therapy. In opposition, phages that are
strictly lytic, also known as virulent phages, are the
ideal weapons to combat bacterial cells, as their multi-
plication always results in lysis of their hosts (Loc-
Carrillo and Abedon 2011). Similar to treatment with
antibiotics, phage therapy also possesses specific prob-
lems, weaknesses and benefits (Table 1). However, this
type of therapy gives the possibility of applying tar-
geted, tailor-made antibacterial agents, providing
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higher specificity than most antibiotics. Furthermore, to
extend the spectrum of activity or to counteract the
emergence of phage-resistant phenotypes, phages may
be delivered as cocktails that extend therapeutic possi-
bilities offered by individual phage strains (Chan
et al. 2013).
Although during recent decades efforts have been
made to isolate and in vitro characterize phages with
therapeutic potential to target different MDR patho-
gens, there is still no consistent and unified account of
phage action in vivo. This review covers the last 10 years
of phage therapy outcomes demonstrated in preclinical
and in clinical trials (Table 2). Major conclusions regard-
ing safety and efficacy assessment of phages against
different in vivo infection models are presented, and
the most important variables that influence the out-
come of phage therapy are discussed.
Pre-clinical trials
Skin and soft tissue infections
Skin infections are a consequence of an integrity break-
age of the skin and they occur frequently. These infec-
tions comprise erythrasma, impetigo, ecthyma,
folliculitis, erysipelas and cellulitis, ranging from harm-
less to life-threatening (O’Dell 1998; Ki and Rotstein
2008). Skin and soft tissue infections (SSTIs) are com-
mon reasons for emergency care settings and hospital-
isations. Indeed, in the USA the number of hospital
admissions due to SSTIs dramatically increased by 65%
from 1997 to 2005 (Hersh et al. 2008). The number of
SSTIs was reported to be stabilised during 2005–2010
with an average prevalence of 48 cases per 1000
person-years (Miller et al. 2015). The skin is colonized
naturally by a diverse population of microorganisms,
where the majority are bacteria (Byrd et al. 2018). The
most humid areas of the body, namely the axilla,
groyne, nares and intertriginous area, are the ones
where larger bacterial populations are found (Grice and
Segre 2011). Although some specific bacteria can colon-
ize specific parts, the composition of the skin micro-
biota depends on climate, age, gender, hygiene
conditions, stress, nutrition habits and site-specific bio-
chemical interactions (SanMiguel and Grice 2015).
Usually, the major cause of SSTIs is wounds, includ-
ing those developed in burn wounds (Church et al.
2006). Also, diabetic foot infections are a major world
epidemic, being a consequence of diabetes mellitus
(Lavery et al. 2006). Patients who develop this type of
infection have a high risk of amputation due to poor
blood circulation, biofilm development on chronic
wounds and also because the bacterial pathogens that
colonize the wound often exhibit antimicrobial resist-
ance to conventional antibiotics (Trivedi et al. 2014).
Antibiotic-resistant bacteria causing complicated SSTIs
are increasingly reported (Eckmann and Dryden 2010):
Staphylococcus epidermidis, Staphylococcus aureus,
Corynebacterium spp., Streptococcus pyogenes,
Pseudomonas aeruginosa, Enterococcus spp., and
Escherichia coli are among the most important causes
of SSTIs in the USA (Moet et al. 2007; Ki and Rotstein
2008; Zilberberg et al. 2009; Jenkins et al. 2010;
SanMiguel and Grice 2015) (Figure 1).
The use of phages for the treatment of SSTIs has
been widely studied and tested in different animal
models (Table 2). The most common in vivo model is
Table 1. Pros and cons of phage therapy.
Pros Cons
Highly specific Pre-diagnosis
By targeting specific bacterial cell wall receptors, leaving untouched the
remaining microbiota. This property favours phages over other
antimicrobials that can lead to dysbiosis (imbalance) of the microbiota
It is compulsory to identify bacterial species and/or strains present in
the infection site, to allow for a rational and personalized phage
therapy
Unique mode of action Neutralization
As they are self-replicating and self-limiting “intelligent drugs”. They
multiply and persist till a minimum number of host cells are still
present. After dealing with the infections, phages are cleared from the
system
As some studies have shown that phages can be removed by the
mononuclear phagocyte system and inactivated by the development of
neutralising antibodies
Synergy Intracellular pathogens
Offering the possibility to be co-administrated with antibiotics or other
phages (cocktail) to limit the appearance of resistant phenotypes. Even
if bacteria develop resistance to phages, they usually are less virulent
As some infections caused by obligatory or facultative intracellular
bacteria (e.g. Mycobacterium leprae, Chlamydia sp.) can invade and
thrive inside human cells, becoming inaccessible for phage therapy
Modification of phages Consumers acceptance
By genome engineering to make up for some disadvantages such as
host range specificity (limited to few strains), limited amplification and
inaccessibility to target intracellular pathogens
Being viruses, the public opinion will ultimately dictate the investment
of pharmaceutical companies and the commercialization of phage
products
Safety
By being constantly present in human microbiome, supplied with food
and as demonstrated in human tests, showing no adverse effect using
different types of administration
Low cost
As they are relatively cheap to isolate and propagate to high titres
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Table 2. Relevant studies about the in vivo application of phages on pre-clinical trials since 2008.
Species (strain) Route Pathogen Main outcome References
Skin and soft tissue infections
Mice
(BALB/c)
Topical K. pneumoniae Burn model. Application of a phage-containing hydrogel
with a MOI of 200 rescued more mice than antibiotics
or chemicals.
Kumari et al. (2011)
Mice
(BALB/c)
Topical K. pneumoniae Burn model. A comparison of the effect of single phage
versus phage cocktail consisting of five phages was
performed. Despite the good results of single phage
therapy, the phage cocktail demonstrated better results.
Chadha et al. (2016)
Rats
(Wistar)
Topical A. baumannii Wound infection in uncontrolled diabetic rats. Using a MOI
of 10, phages were locally sprayed and results were
compared with the antibiotic colistin. Phage treatment








A. baumannii Phage Abp1 topical application resulted in smaller wound
sizes than in injected wounds.






A phage cocktail comprising six phages was used on
chemically induced diabetic rats. Although phage
treatment decreased significantly bacterial cell counts
and improved wound healing, the effect was shown to
be pathogen-dependent. The best results were obtained
when phage was administrated after wound
debridement.






A phage cocktail comprising six phages was used on pig
wound infection model. The results were species-
dependent, but in general there was a synergism with
mechanical debridement. Improvements were more
significant in the rodent model than in the porcine
model.
Mendes et al. (2013)
Mice
(Male albino)
Injection P. aeruginosa Wound model. A phage cocktail comprising 11 phages was
added into subcutaneous pockets containing two
biofilm-laden catheter sections, demonstrating a
significant decrease on the number of bacterial cells
and a rise on the number of phages.
(Basu et al. 2015)
Mice
(BALB/c)
Local injection S. aureus Phage MR-10 was administered locally on alloxan induced
diabetic mice with diabetic foot infection. Using a MOI
of 100 results were similar with linezolid. Combined
treatment was more effective.
(Chhibber et al. 2013)
Mice
(BALB/c)
i.p. E. coli Mice bearing tumours had been subjected to tumour
surgery before the experiment. Surgical wounds were
infected with E. coli and engineered T4 phage
displaying tumour-specific peptides was used for
combined treatment. The acuteness of wounds, bacterial






i.p. K. pneumoniae Burn model. A single injection of phage Kpn5 at a MOI of
1 rescued significantly mice when administrated
immediately and even after 18 h of bacterial challenge.
Kumari et al. (2010)
Mice
(BALB/c)
s.c. M. ulcerans Mice treated with a single injection of the
mycobacteriophage D29 presented decreased footpad
pathology associated with a reduction of the bacterial
burden.
Trigo et al. (2013)
Rat
(Wistar)
i.m. S. aureus Transfersome-entrapped phage cocktail healed thigh
infections after 7 days, being infections of untreated
animals resoled only after 20 days.
Chhibber et al. (2017)
Eye and ear infections
Mice
(C57BL/6)
Topical P. aeruginosa A single dose of phage eye-drops significantly improved
keratitis, suppressing neutrophil infiltration and bacterial
clearance in the cornea.
Fukuda et al. (2012)
Mice
(C57BL/6)
Topical P. aeruginosa A single phage cocktail successfully controlled and




Dog Topical P. aeruginosa A single phage cocktail dose (105 PFU/ear) applied directly
to the auditory canal significantly reduced clinical scores
after 48 h, without inflammation or other adverse events
detected.
Hawkins et al. (2010)
Dog Topical P. aeruginosa A small dose of phage (400 PFU) was enough to cure a
chronic otitis.
Marza et al. (2006)
(continued)
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Table 2. Continued.





i.n. S. aureus A single phage (MOI 1 or 10) completely decolonised S.
aureus from nares at day 7 after treatment, as
compared to untreated group. Mupirocin treatment had
a similar effect. Phage with mupirocin achieved
complete clearance at day 5.
Chhibber et al. (2014)
Sheep
(Marino-cross)
i.n. S. aureus A phage cocktail (106 PFU/ml) used to flush frontal
sinusitis once daily for 3 days were proved to
decolonise nares and to be safe for short-term
applications. EDTA treatment has a similar effect. Phage
and EDTA did not synergized.
Drilling et al. (2014)
Sheep i.n. S. aureus A phage cocktail was proved to be safe for long-term
applications. Flushing frontal sinusitis for 20 days with
phages revealed not to cause side effects, inflammatory
responses or tissue damage.
Drilling et al. (2017)
Sheep
(Merino)
i.n. P. aeruginosa Phage cocktail applied twice daily (108 to 1010 PFU/ml)
significantly reduced a 7-day old biofilm in sheep
frontal sinuses, without safety concerns observed.




i.n. K. pneumoniae Phages (109 PFU/mouse) added 2 h after infection reduce
the bacterial load in the lungs and increase survival rate
of mice (80%) compared with mocked-treated group






i.n. P. aeruginosa Curative treatments rescued 95% of immunocompent mice
when applying phages with 108 PFU/ml, 2 h after
infection. A 4-day preventive treatment resulted in a
100% survival.
Morello et al. (2011)
Mink
(Jinzhou Black)
i.n. P. aeruginosa Alternative model to study haemorrhagic pneumonia.
Challenged mink received phage treatment 2-h post-
infection. At 12 days, 80% of mink survived with phages





i.n. P. aeruginosa Phages added at MOI of 10 could complete clear lung
from infection either added at 24, 36, and 48 h post
infection. UV-inactivated phages did not have protective
effect.
Waters et al. (2017)
Mice
(BALB/c)
i.n. P. aeruginosa Phage cocktail reduced biofilms in a cystic fibrosis
bronchial epithelial CFBE41o-cells. Tests in infected mice
with a lux tagged strain, showed a reduction of 4 logs





i.n. vs. i.p. B. cenocepacia Comparison of different phage administration routes. One
day after infection, i.n. delivered phage significantly
decreased bacterial load in the lungs and was more
efficient than i.p. treatment.
(Semler et al. 2014)
Mice
(BALB/c)
i.p. K. pneumoniae Liposome-entrapped phages could treat pneumonia at
3 days or prevent the disease 1 day prior infection.
Nonliposomal could only treat mice at 1 day or prevent
pneumonia when added 6 h before challenge.
Singla et al. (2015)
Mice
(BALB/c)
i.p. K. pneumoniae A single phage dose (1010 PFU/ml) administered
immediately rescued 100% of animals from K.
pneumoniae-mediated respiratory infections, but a 6 h
delay in treatment was ineffective.
Chhibber et al. (2008)
Mice
(BALB/c)
i.v. S. aureus Phage (108 PFU/ml), dindamyxin (8mg/kg of body weight)
or combined treatments had similar mice survival rates.
In lung tissues, it resulted in lower 0.5, 4.4, and
4.0 CFU/gm bacterial load, respectively, compared with
non-treated group (8 CFU/g).
Oduor et al. (2016)
Sheep Extension
cannula
S. aureus Long-Term administration of NOVO12, (a cocktail
composed of two phages) locally applied to the frontal
sinus for 20 days was regarded as safe, without
inducing inflammatory responses or tissue damaged.





P. aeruginosa A phage dry-powder formulation (2mg/mice) applied 2 h
after the bacterial challenge, decreased the bacterial
load in the lungs by 5.3 log, compared with non-treated
group.
Chang et al. (2018)
Mice
(C57BL/6)
i.p. P. aeruginosa Single phage treatments (109 PFU/ml) significantly
decreased the infection in the lungs (>4 logs) and
protected mice (>65%) from an otherwise deadly
infection, when applied 4 h post-infection.
Jeon and Yong (2019)
Mice
(BALB/cJRj)
i.v. E. coli Phages cleared lung infection faster than antibiotics, but
both displayed similar endpoint. The rapid lysis of
Dufour et al. (2019)
(continued)
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Table 2. Continued.
Species (strain) Route Pathogen Main outcome References
bacteria did not increase the innate inflammatory




Oral E. coli Phages were able to specifically kill E. coli added to mice
without having impact on the commensal flora. Doses






Oral E. coli O104:H4 Demonstration of the different E. coli susceptibility profiles
to phage in mice gut. Strains collected from the ileum
were sensitive to all three phages, while those from
faeces were infected by only one.
Maura et al. (2012)
Mice
(BALB/c)
Oral E. coli Phage orally given (109 PFU/ml) protected mice from
salmonellosis and prevented weight loss after 10 days
of treatments.
(Nikkhahi et al. 2017)
Mice
(BALB/c)
Oral E .coli A single dose of phage (109 PFU/ml) protected mice from
enteropathogenic E. coli during the 10 days of the
study.
(Vahedi et al. 2018)
Mice
(Swiss Albino)
Oral V. cholerae Phage cocktail (108 PFU/ml and ciprofloxacin (40mg/Kg)
given once daily could reduce the bacterial load by 3
and 5 logs/g of tissue homogenates, respectively.
Rehydration treatment supplied in the drinking water
did not reduce the bacterial counts but could diminish
the cholera infection in a higher extent.
Jaiswal et al. (2014)
Hamster
(Syrian golden)
Oral C. difficile Phage cocktail (108 PFU/ml) significantly reduced bacterial
colonisation at 36 h post-infection. Phage treatments
also delayed the onset of symptoms by 33 h compared
to the time of onset of symptoms of control groups.
Nale et al. (2016)
Mice
(BALB/c)
Oral V. parahaemolyticus Mice treated with phage 1 h after inoculation with bacteria
were protected from infection and death caused by i.p.
administration of bacteria (MOI 10).
Jun et al. (2014)
Rabbit Oral
(gastric tube)
V. cholerae Phage cocktail (108 PFU) could significantly reduce
shedding of bacteria when administrated 6 and 12 h
after challenge. No effects were obtained using profilatic
treatment, 6 and 12 h prior-infection.





E. coli A single dose of phage cocktail decreased bacterial
throughout the gut with a lower impact on microbiota
composition comparatively to antibiotic treatment.




i.p. E. coli Administration of T4 and KEP10 phages caused a marked
decrease in the mortality of mice inoculated
transurethrally with a UPEC strain. Phages were
administered in MOIs 0.01–60, they were effective in





i.p. C. turicensis Administration of phage (1011 PFU/ml) immediately after
challenge reduced the bacterial burden in the kidney by
70%, rescued the levels of meondialdehude and did not
affected the antioxidant status.
Tothova et al. (2011)
Mice
(Kunming)
i.p. S. enteritidis Phage single dose (1010 PFU/mouse) 1 h after bacterial
challenge protected 40% of mice from a lethal infection.




i.p. K. pneumoniae A phage cocktail of three phages was applied in a step-by-
step approach reducing the emergence of phage-
insensitive mutants. Furthermore, phage cocktail rescued
more mice than single phage approach.
Gu et al. (2012)
Mice
(BALB/c)
i.p. P. aeruginosa A single phage administration (MOI of 100) rescued 100%
when phage was injected 45min after bacterial
challenge. Even when mice was moribund a single





i.p. P. aeruginosa A single phage was administered on immunocompetent
and on neutropenic mice using different MOIs (1, 10,
and 100). Normal mice were rescued by 80–100% with
all MOIs tested. Infected neutropenic mice were not
protected by the phage.
(Tiwari et al. 2011)
Mice
(ICR)
i.p. E. faecalis A single injection of a phage cocktail consisting of two
different phages at a MOI of 0.02 rescued all mice when
administered 1 h after bacterial challenging.
Gelman et al. (2018)
Mice
(ICR)




i.p. S. aureus Sunagar et al. (2010)
(continued)
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the wound model in mice (Basu et al. 2015; Yin et al.
2017) including burn models (Kumari et al. 2010, 2011;
Chadha et al. 2016), tumour surgery wounds
(Dabrowska et al. 2014) and footpad injury (Trigo et al.
2013). Nevertheless, the possibility of phages to combat
infected diabetic foot ulcers was also assessed in two
different animal models—rat and porcine. As these
infections are often polymicrobial, a phage cocktail cov-
ering three different pathogens was administered topic-
ally, and although successful in both models,
improvements were more significant in rats (Mendes
et al. 2013).
The majority of the in vivo phage therapy studies for
SSTIs were performed using phage cocktails rather than
single phages. Nevertheless, Chadha et al. (2016) com-
pared the effect of single phage versus phage cocktail
therapy in a burn wound infection model in mice. The
authors isolated five new Klebsiella pneumoniae phages
and applied them topically, either individually or in
combination. Although monotherapy was able to
reduce bacterial load, the phage cocktail demonstrated
better results.
In several studies, only a single phage administra-
tion was applied using different multiplicities of infec-
tion (MOI), that represent the ratio of phage particles
to bacterial cells. In a murine burn wound model it
was found that when phages were topically applied at
MOI of 200, the level of phage-derived protection was
higher than that offered by chemicals or antibiotics
(Kumari et al. 2011). In another study, using a hindpaw
infection in diabetic mice, Chhibber et al. (2013) dem-
onstrated the effect of a single administration of
phages (MOI of 100) in combination with linezolid. A
significant effect was noted on resolving the course of
infection by following the development of infection,
namely the bacterial load, lesion score, histological
examination and myeloperoxidase activity (Chhibber
et al. 2013). Also Trigo et al. (2013) demonstrated that
a single subcutaneous (s.c.) injection of a relevant
phage decreased bacterial burden and negative
Table 2. Continued.
Species (strain) Route Pathogen Main outcome References
Mice
(BALB/c)
Phage GRCS rescued both diabetic and non-diabetic mice
by 90 and 100%, respectively. Phage was more efficient
in reducing cell counts than oxacillin.
Mice
(BALB/c)
i.p. E. faecalis A single injection using a low MOI 1 h post-infection
rescued all mice. Phage treatment affected the balance
of the gut microbiota community in a dose-dependent
manner.
Cheng et al. (2017)
Mice
(BALB/c)
i.p. A. baumannii Both phage Abp1 and polymyxin B rescued all treated
mice. The phage found in liver and kidney at high titres
suggested in vivo replication.
Yin et al. (2017)
Mice
(BALB/c)
i.p. V. parahaemolyticus Mice treated with phage 1 h after inoculation with bacteria
were protected from systemic infection and death
caused by i.p. administration of bacteria (MOI 10).
Jun et al. (2014)
Mice
(ICR)
i.p. and i.m. P. aeruginosa Two different phages were used. Although i.m.
administration showed better pharmacokinetics, i.p.
injection was more efficient rescuing mice.





K. pneumoniae Evaluation of i.g vs. i.p. delivery during the course of liver
infection. i.g. delivery offered higher protection at early
phage administration (30min), while i.p. injection
demonstrated better results at late phage
administration (6–24 h).
Hung et al. (2011)
Rat
(Sprague Dawley, pups)
i.p. or s. c. E. coli Phage administered 7 or 24 h post-infection resulted in
100 and 50% of rats survival, respectively.






Phage isolated from faeces of patients with gastroenteritis
had life-saving effect in mice when administered right
after inoculation with bacteria at MOI 1 or in delayed
treatment (2 weeks after infecting mice with sublethal






i.v. E. coli A single phage dose was highly efficient when






i.v. P. aeruginosa Endocarditis. Administration of the phage cocktail 18 h
after bacterial challenge by either continuous or bolus
injection decreased median vegetation bacterial titres by
3.0 and 2.3 log CFU/g, respectively, within 6 h of
therapy.
Oechslin et al. (2017)
Rat
(Wistar)
i.m. E. faecalis After periapical lesion induction, treatment with phage
cocktail formulated with poloxamer P407 reduced 99%
of the intracanal viable bacterial counts, with reduced
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symptoms in mouse models of footpad infection with
Mycobacterium ulcerans.
Chadha et al. (2017) demonstrated the potential of
treating burn wound infections with a liposome-encap-
sulated cocktail of five K. pneumoniae newly isolated
phages. The encapsulated cocktail was more efficient in
reducing bacterial load than free phage cocktail being
able to rescue all the animals tested. The authors sug-
gested that this difference was possibly related with lip-
osomes higher retention within the body (Chadha
et al. 2017).
The route of administration of phages has been
shown to have an important impact in the outcome of
the wound treatment. A cocktail of three phages was
administered by MacVay et al. (2007) in a single dose
by three different routes, intramuscular (i.m.), intraperi-
toneal (i.p.) and s.c., after mice had been burned and
infected with a fatal dose of P. aeruginosa. Although all
the routes of administration increased mice survival, i.p.
injection was the most successful one. The differences
in the efficacy may be a consequence of different
pharmacokinetics of phage after different application
routes. As the authors noticed, i.p. administration
allowed phages to disseminate in the system earlier
and at a higher dose than the other routes of adminis-
tration (McVay et al. 2007).
Despite several studies used topical or systemic
administration of phages, only a few have compared
their efficacy. Recently, the s.c. application versus top-
ical application of phage Abp1 was tested in mice
wounds infected with Acinetobacter baumannii. The
authors observed that the topical application of phage
resulted in smaller wounds than in s.c. injected mice
(Yin et al. 2017), suggesting that topical application is
probably a good choice in wound treatment.
Mendes et al. (2013) pointed out that a phage cock-
tail administered topically was more effective when
added after a wound debridement treatment. Although
all the phage treatments were able to significantly
reduce bacterial cell counts and improve wound heal-
ing in animal models, the efficiency of the phage cock-
tails varied according to the target bacteria as it was
not so effective against A. baumannii (<1 log reduction)
as it was against P. aeruginosa (4 log reduction) and S.
aureus (3 log reduction) (Mendes et al. 2013).
The aforementioned studies have shown the poten-
tial and efficacy of phages to treat bacterial infections
of skin and soft tissues, namely using topical but also
parenteral application of phages (Figure 1). However, it
is important to highlight that the majority of these
studies were tested on models of acute infection,
mainly due to the difficulties in establishing chronic
models of infection. There are other emerging patho-
gens causing SSTIs, namely Cultibacterium acnes,
Mycobacterium marinum, Mycobacterium szulgai,
Treponema pertenue and Actinomadura madurae, for
which there are no data available and consequently,
further studies on these microorganisms should be
performed.
Eye, ear, and dental infections
Eye infection can occur when pathogens invade and
colonize the cornea or the conjunctiva. Methicillin-
resistant S. aureus (MRSA) is the most common eye
pathogenic agent, causing for example conjunctivitis,
preseptal cellulitis and/or lid abscess, keratitis,
endogenous endophthalmitis, orbital cellulitis and ble-
bitis (Blomquist 2006). Other bacterial pathogens such
as E. faecalis and P. aeruginosa also cause these types of
infections (Gorski et al. 2009). Although the risk of
spreading is high and millions of people suffer from
conjunctivitis on a daily basis, epidemiological data are
limited.
Recently, the P. aeruginosa phage KPP12 was isolated
and characterized, and its ability to treat keratitis in
mice was assessed. KPP12 was administered as eye
drops of 108 PFU/ml to P. aeruginosa infected eye. The
results showed that a single phage dose controlled the
infection, preserving the corneal structure (Fukuda et al.
2012). More recently, a phage cocktail composed of
two phages was also applied as eye drops to combat a
P. aeruginosa keratitis infection in mice. The results
revealed that the phage treatment was successful when
the cocktail was applied within 3 h post-infection using
an MOI of 100 (Furusawa et al. 2016). Although there
are few reports on phage therapy in eye infections,
both studies have shown efficacy with no side effects
reported, emphasizing that phage-containing eye drops
can be a promising approach to treat eyes with anti-
biotic-resistant infections (Figure 1).
Otitis is a general term for inflammations and infec-
tions of the inner, middle or outer ear. Acute otitis
media is a common problem and a leading cause of
health care visits and antibiotic prescription in children,
where it affects up to 75% of children up to the age of
5 years (Klein 1994). P. aeruginosa is one of the more
prevalent chronic externa and media otitis causative
agents. In a veterinary study, a cocktail of six different
phages was developed and used as a treating agent in
13 dogs with chronic P. aeruginosa otitis (Hawkins et al.
2010). The cocktail was topically administered into the
auditory canal in a concentration of 1 105 PFU/ml of
each phage. The clinical score and bacterial counts
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were decreased at 48 h after treatment, with no adverse
effects detected.
Despite the lack of other studies of otitis in animal
models, the topical application of phage to cure outer
ear infections seems to be justified. In more inaccessible
zones such as the media or the inner ear, phage inhal-
ation could be a valuable therapeutic complement
(Mirandola et al. 2013). Also, further tests in other rele-
vant otitis-causing agents should be addressed, namely
against Haemophilus influenzae, Streptococcus pneumo-
niae and Moraxella catarrhalis (Broides et al. 2009).
Dental infections are infections that occur at tooth
or tooth-supporting structures and that can be easily
spread throughout the surrounding tissue. These infec-
tions usually occur after trauma, development of dental
caries or dental procedures where bacteria gain access
to the dental pulp and spread to the adjacent tissues.
In the USA, it is estimated that more than 20% of the
population have untreated dental caries, and around
75% has at least one dental restoration during their life-
time (Dye et al. 2012). The prevalence of caries and con-
sequently of dental infections is dynamic during
lifetime being more present in adulthood in compari-
son with childhood (Beltran-Aguilar et al. 2005;
Pourhajibagher et al. 2017). In a recent study, a polox-
amer P407 formulation containing enterococci phages
EFDG1 and EFLK1 phages were applied in a rat root
canal infection model. The formulation was injected
into the root canals being further spread intracanal dur-
ing gelation process and finally sealed. The treatment
lasted for 3 weeks and the formulation reduced by 99%
enterococci cell counts (Shlezinger et al. 2019). Even
with few studies applied on this type of infections, fur-
ther studies could target other relevant pathogens
including streptococcal and non-streptococcal bacteria
(e.g. Bifidobacterium spp., Scardovia spp. and
Actinomyces spp.) and anaerobic pathogens more pre-
sent on the subgingival area, namely Bacteroidaceae
spp. and spirochaetes (Lamont et al. 2018). Moreover,
the use of phage therapy has been suggested to be
applied to other oral pathologies, namely periodontitis
(Pinto et al. 2016).
Respiratory tract infections
Respiratory tract infections (RTIs) are generally distin-
guished as upper respiratory (if located in the nose,
sinuses or throat) or lower respiratory (if located in
bronchi or lungs) infections. Depending on the type of
infection (e.g. sinusitis, pneumonia), the way of contrac-
tion (i.e. nosocomial versus community-acquired), and
other factors (e.g. whether patients are immunocom-
promised), several microbes can colonize the mucosa.
In the upper respiratory tract there is a predominance
of viral infections, but they often pre-dispose patients
to secondary and severe bacterial infections (Juven
Figure 1. Different studied phage applications to treat the most common types of infection.
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et al. 2000). In fact, bacterial infections are observed in
60% of patients with upper RTIs, with H. influenzae,
S. pneumoniae, M. catarrhalis, K. pneumoniae and
Streptococcus pyogenes being the most commonly
involved pathogens (Stensballe et al. 2003; Wardlaw
et al. 2006) (Figure 1). Bacterial infections are even
more common in the lower respiratory tract and more
life-threatening, especially for children under 5 years.
About 20% of children hospitalizations are diagnosed
with respiratory diseases, and of those, 90% are pneu-
monias (World Health Report 2008). This scenario leads
to 2.2 million childhood deaths annually, according to
the latest surveillance report from the WHO (Williams
et al. 2002; World Health Organization 2011). Less fre-
quent, but equally important, are lung infections of
patients suffering from cystic fibrosis (CF). CF is a gen-
etic disorder characterized by increased mucus clogs in
the airways and lungs. Burkholderia cepacia and P. aeru-
ginosa play an important role in CF pathogenesis as
opportunistic pathogens often displaying high anti-
biotic resistance. P. aeruginosa poses a special risk to CF
patients as it represents 80% of the total pulmonary
infections (Hoiby 2011). Although a smaller fraction of
infections is caused by B. cepacia, the prognosis for CF-
infected patients is poor, with an increased risk of death
(Govan et al. 2007).
Upper respiratory infections
Probably due to lower severity, the application of
phages against upper respiratory infections is less rep-
resented, compared with infections located in the lower
sites of the respiratory tract (Table 2). To our best know-
ledge, only four studies have aimed to decolonize
nares, three from S. aureus and one from P. aeruginosa.
Two types of animal models were used, mouse and
sheep. In both, the nasal tissue was exposed to bacteria
and subsequently to phages, after which the tissue was
extracted for histological analysis and assessment of
the bacterial load. The results showed that, although
phages were able to decolonize nares from S. aureus,
the effect was similar to that achieved with antibiotics
or chelating agents. Chhibber et al. (2014) compared
intranasal (i.n.) administration of phage (MOI of 1) to
the treatment with mupirocin and a significant reduc-
tion (>2 log reduction) of MRSA from nares of mice
7 days after challenge was observed. Combination of
both phage and mupirocin led to the complete eradica-
tion of MRSA even at day 5. Drilling et al. (2014) studied
the efficacy of topical application of a phage cocktail
flushed daily for 3 days to treat sinusitis in a sheep
model. The significant reduction of biofilm formed on
the extracted sinuses showed an effective short-term
treatment of the sinus mucosa affected by S. aureus
mucosal biofilms. EDTA is a metal chelator with thera-
peutic potential against biofilms, so the authors com-
pared its effect with the phage cocktail. It was also
shown that EDTA-treated nares demonstrated a similar
effect (to that in phage-treated nares), and no synergy
was obtained when EDTA was combined with phages.
These two studies highlight that applications of a
single phage and phage cocktails are possible means to
reduce the nasal bacterial load. However, the use of
phage cocktails covering a wider host range is crucial
for successful nasal decolonization in clinical settings.
The administration of higher phage doses would pos-
sibly be beneficial for sinusitis treatment as well as the
phage combination with other active agents, as demon-
strated with mupirocin.
To investigate the safety of longer-term treatments,
Drilling et al. (2017) conducted a second study where
they flushed the frontal sinus of sheep contaminated
with S. aureus with a phage cocktail for 20 days. No side
effects, inflammatory responses or tissue damage were
observed. Similar findings were obtained by Fong et al.
(2019), who applied a P. aeruginosa phage cocktail
twice daily to the frontal sinus of sheep for 3weeks,
with no adverse effects observed.
Taken together, the phage therapy in the field of rhi-
nology to control sinonasal bacterial biofilms seems to
be a safe and promising approach, independently of
animal model, type of phage (single or cocktail) or dose
(single or multi) when administered intranasally
(Figure 1).
Lower respiratory infection
Lower respiratory infections can be life-threatening and
therefore have been extensively studied by phage sci-
entists, in mice and mink models (Table 2). Mouse mod-
els have been widely used for testing phages in
pulmonary infections caused by K. pneumoniae, B. cepa-
cia, P. aeruginosa, A. baumannii and S. aureus. Cao,
Wang, et al. (2015) demonstrated that mice infected
with a MDR K. pneumoniae (108 CFU/mouse) could be
controlled by phage 1513 (107–109 PFU/mouse) applied
i.n. 2-h post-infection. Also, the cytokine levels (tumour
necrosis factor a and interleukin-6) in the lung tissue of
phage-treated mice were remarkably lower than those
of the control mice, demonstrating the anti-inflamma-
tory effect of the treatment and thus documenting the
potential of phage therapy as alternative treatment in
pneumonia caused by MDR pathogens. The mink
model of haemorrhagic pneumonia was also explored
by Cao, Zhang, et al. (2015). The authors collected
P. aeruginosa strains from minks with lung infection
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and isolated a lytic phage PPA-ABTNL against that
bacterial strain. Minks were challenged with 108 CFU of
P. aeruginosa and treated i.n. with phage (MOI of
1–100) 2 h later. A MOI of 10 proved to be enough to
treat haemorrhagic pneumonia with an 80% survival
rate scored 12 days after phage administration.
The phage administration dose to treat RTIs can be
detrimental. Debarbieux et al. (2010) implemented a P.
aeruginosa acute lung infection in mouse models and,
in curative treatments, applied phages i.n. Phages had a
protective effect when applied 24 h before bacterial
infection. Moreover, they saved mice when applied 2 h
after inoculation with bacteria. This positive effect was
however dose-dependent, as 100% of the animal sur-
vival was achieved only with a MOI of 10. Jeon et al.
(2016) also demonstrated a dose-dependent effect in
the treatment of A. baumannii-induced pneumonia in
mice. The authors showed that the i.n. application of
phage 30min after bacterial inoculation could clear the
pathogen from the lungs within 3 days and that the sur-
vival rates of mice varied from 100%, 50% to 16% when
treated with phage at MOI of 10, 1 or 0.1, respectively.
Regarding the administration route, generally, a pro-
tective effect of phages has been observed after their
administration by the i.n., i.p., or i.v. route or endotra-
cheally. The most popular route to treat respiratory
infections was i.n. administration (Table 2). Alemayehu
et al. (2012) applied i.n. a phage cocktail that was
effective in killing lux-tagged PAK mucoid CF strain in
murine lungs. The light emitted by labelled pathogen
cells from the control mice reached a maximum at 6 h
after infection, and it was significantly decreased in
mice treated with phage during the same period. In
addition to therapy with a phage cocktail, treatments
with single phages have shown to be equally success-
ful. The group of Debarbieux also proved that a single
i.n. application of phage to immunocompetent mice 2 h
after infection could rescue 95% of treated mice
infected by a MDR mucoid P. aeruginosa strain (named
CHA) isolated from a CF patient of Grenoble hospital in
France (Morello et al. 2011). Roach et al. (2017) reported
an interesting study showing that the functional
immune system was essential for the effectiveness of
phage therapy. The authors applied phages i.n. against
P. aeruginosa induced pneumonia using several mice
strains and conditions: (i) wild type healthy immuno-
competent, (ii) MyD88-deficient, lymphocyte-deficient
and (iii) neutrophil-depleted mice. The results demon-
strated that neutrophils were required to control
phage-sensitive and emergent phage-resistant bacteria,
emphasising the need to complement phage therapy
in order to increase its efficacy in patients with
immunodeficiencies.
All the examples mentioned above demonstrated
the high applicability of the i.n. administration route,
but other routes of phage administration have also
been studied. Oduor et al. (2016) showed that S. aur-
eus-induced pneumonia in mice can be treated by
injecting phage i.v. Phage was administered at 108 PFU/
ml and it reduced the bacterial load from 8 CFU/g in
the non-treated group control to 0.5 CFU/g in the lung
tissues. The authors also showed that clindamycin
(8mg/kg of body weight) or combined treatments with
phage could also reduce the bacterial load, but was not
as efficient as phage-alone treatment. Antagonistic
effects may be explained by the bacteriostatic effect of
clindamycin that can hinder protein synthesis in bac-
teria together with subsequent phage proliferation.
Carmody et al. (2010) compared i.n. and i.p. administra-
tion routes in mice, revealing that i.p. administration of
BcepIL02 phage was more effective to control acute
Burkholderia cenocepacia lung infection. However,
Semler et al. (2014) contradicted that study, by showing
that aerosol dissemination of the phage KS12 was more
effective than i.p. injection of phages to treat B. cenoce-
pacia RTI. A similar MOI was used, indicating that the
differences observed can possibly be attributed to the
bacterial strain, infectious dose, phage species or other
factors related to animal experiments such as the mice
strains. One elegant approach to improve i.p. efficacy
was demonstrated by Singla et al. (2015), who
improved pharmacokinetics of phage by entrapping
virions into liposomes. The authors achieved effective
therapy with liposome-entrapped phages (3 days post-
infection) or prophylactics (24 h prior infection) against
K. pneumoniae-induced lobar pneumonia. In contrast,
free phages (nonliposomal) were only effective when
administered 1 day post-infection or 6 h prior infection.
Reduction of the inflammatory markers further sup-
ported the superior effect of liposomes as delivery
vehicles of phages.
A possible solution to improve phage delivery is
dry-powder products, which could facilitate storage,
transport and standardize phage administration.
Chang et al. (2017) and Chang et al. (2018) validated
this option by formulating a phage spray with lac-
tone and leucine to promote higher stability during
spray drying and protection from moisture, respect-
ively. This phage preparation administered via the
endotracheal route could reduce by 5 log the bacter-
ial load in the lungs of mice infected by P. aeruginosa
after 24 h. No adverse effects were observed in
healthy mice.
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Despite the general success of phage therapy in
in vivo models, one important issue is related to the
fact that in the studies discussed herein phages were
only applied a few hours (usually 2 h) after infection,
which can only be translated to starting treatment at
an early stage of infection. To address this issue, Waters
et al. (2017) reported the first study showing the effect-
iveness of phage treatment up to 7 days post-infection.
The authors reported that phages administered i.n. at a
MOI of 10 could completely clear the P. aeruginosa
from infected lungs either when applied at 24, 36 or
48 h post-infection, encouraging the potential use of
phage therapy against established long-term chronic
lung infections.
Another important concern is the lack of clear guide-
lines to choose phage strains applicable in therapies.
Therefore, Henry et al. (2013) proposed, for the first
time, a reliable index to predict phage treatment effi-
cacy. Using the bioluminescent P. aeruginosa PAK strain,
a well-established mouse lung infection model and a
real-time imaging system, the in vivo effectiveness of
phage therapy was assessed. In this model, the authors
demonstrated that phage infectivity in vitro cannot
always be directly extrapolated to good in vivo efficacy.
The authors also observed that phages isolated directly
on the targeted host were the most efficient, support-
ing a personalized approach favouring optimal
treatment.
Concerning the safety aspect of phage treatment,
Dufour et al. (2019) used a murine E. coli caused acute
pneumonia model and assessed the treatment with
phages or antibiotics (ceftriaxone, cefoxitin and imi-
penem-cilastatin). The authors demonstrated that while
both treatments could significantly reduce the lung
infections, they had similar endpoints. Interestingly,
they also reported that phages could control the infec-
tion more quickly than the antibiotics and phage treat-
ment did not result in an increase of innate
inflammatory response (due to the release of bacterial
debris) when compared to the antibiotic treatments.
Taken together, phage effectiveness to treat RTIs
seems to be strongly dependent on the infection type
and route of phage administration. Generally, the i.n.
administration seems to provide more promising
results. While some common respiratory pathogens
have been studied (e.g. K. pneumoniae, B. cepacia, P.
aeruginosa, A. baumannii, S. aureus), surprisingly, no
studies on the deadliest respiratory bacterial pathogens,
such as S. pneumoniae, H. influenzae or Mycoplasma
pneumonia, have been reported so far. Moreover, there
are no current animal models that mimic the increased
formation of mucus clogs in the airways and lungs,
typical of CF disorder, and that can have a significant
impact on phage efficacy.
Gastrointestinal tract infections
Gastrointestinal tract infections (GTIs), also known as
gastroenteritis, are inflammations of the stomach and/
or intestines that result from acute enteric infections
and diarrheal diseases. Based on epidemiological stud-
ies, it is estimated that 5 billion cases of gastroenteritis
occur annually, which result in 1.4 million deaths world-
wide (Elliott 2007; Lozano et al. 2012). Furthermore,
GTIs represent the leading cause of infant mortality.
Outbreaks of gastroenteritis are caused by frequent
bacterial pathogens such as E. coli, Campylobacter jejuni,
Salmonella Enteritidis and Listeria monocytogenes, and
also by less frequent but still significant Clostridium diffi-
cile and Vibrio cholerae. These infections often occur as
a result of poor sanitation, lack of safe drinking water or
contaminated food (Figure 1) and are typically known
as food poisoning.
To treat human GTIs, phage effectiveness has been
studied in animal models (mice, rabbit and hamster).
Generally, phages are able to survive in the GI tract,
and most importantly, they protect animals from GTIs.
In mouse models, Denou et al. (2009) showed that a T4-
like coliphage cocktail (109 PFU/ml) administered with
drinking water to infected animals could reach the duo-
denum and the distal parts of the gastrointestinal tract
without causing mice weight loss or abnormal behav-
iours, which is a prerequisite of the phage effectiveness
to control GI tract pathogens. Nevertheless, Maura et al.
(2012) clearly demonstrated that bacterial susceptibility
to phage infection is not uniform throughout the gut.
Feeding mice with three different E. coli O104:H4-infect-
ing phages in the drinking water 24 h after bacterial
challenge, the authors showed that the O104:H4
55989Str strain present in the ileum was sensitive to all
phages, but the cells recovered from faeces were per-
missive to only one. In addition, the therapeutic treat-
ment with a phage cocktail had only a transient effect
as the bacterial levels in the ileum and faeces restored
their initial concentrations after the third day, even
though the phage titre was maintained relatively high
(Nikkhahi et al. 2017). E. coli probably becomes resistant
as a response to phage predation, similarly as observed
with Campylobacter in the avian gut (Scott et al. 2007).
However, other reports have shown the success of
phages in controlling diarrheal diseases in mice,
although in some cases antibiotic treatment (ciprofloxa-
cin) was found to exert a similar or even better
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antimicrobial effect (Jaiswal et al. 2014; Nikkhahi
et al. 2017).
In a rabbit model of cholera infection, Jaiswal et al.
(2013) demonstrated that phage cocktails could reduce
V. cholerae burden when given 6 and 12 h after bacter-
ial challenge. Similarly, Jaiswal et al. (2014) compared
phage cocktail with antibiotics and with oral rehydra-
tion treatments to control V. cholerae infection, by
applying each treatment orally over a 3-day period.
Whereas oral rehydration had no effect, phages could
reduce the bacterial burden (by 3 log10/g), but max-
imum protection was achieved by ciprofloxacin treat-
ments (reduction of >5 log10/g). In a hamster model,
Nale et al. (2016) showed that a phage cocktail could
significantly reduce C. difficile colonisation at 36 h post-
infection and it delayed the onset of disease symptoms
by 33 h. This demonstrates the potential of phages to
control bacterial infections in the gut.
The choice between a mono-phage therapy and
phage cocktails seems to favour the latter for the possi-
bility of covering a wider range of strains capable of
causing clinical diseases. Although both strategies have
successfully been used to control enteric pathogens,
phage cocktails have been the most often reported.
The time of administration, however, seem to be rele-
vant. While reports show that phages are able to reduce
pathogens several hours post-infection, prophylactic
applications seems to be less efficient. This was shown
in the experiment by Jaiswal et al. (2013) where phages
reduced the shedding of V. cholerae when given 12 h
post-infection, but had no effect when added prior to
bacterial challenge. It is possible that at least some
phages maintain their ability to infect bacteria relatively
briefly when administered orally; thus concentrations of
active phage drop to inefficient levels before they
encounter sensitive bacteria.
Concerning the mode of administration, many mod-
els comprised phages applied continuously with drink-
ing water or by serial dosing, but administration of
single phage doses by oral or intracloacal gavage is
also possible. Nikkhahi et al. (2017) evaluated the effect
of a single phage dose (109 PFU/mouse) to treat sal-
monellosis induced by Salmonella Enteritidis, applying
them with an oral gavage syringe 4 days after chal-
lenge. Phage treatment protected mice from salmonel-
losis and prevented weight loss in mice as a disease
symptom. Ciprofloxacin used as a positive control had a
similar protective effect but it did not protect against
weight loss. Similar results demonstrating the effective-
ness of single doses of phage were obtained by Vahedi
et al. (2018), who controlled enteropathogenic E. coli in
mice, and by Jun et al. (2014), who successfully treated
mice infected with Vibrio parahaemolyticus (marine bac-
terium causing infections associated with consumption
of raw oysters). Jaiswal et al. (2013) also showed that
phages administered orally to rabbits by gastric tube 6
and 12 h post-infection controlled V. cholerae infections.
Taken together, phages seem to have a potential to
control enteric pathogens as demonstrated in many
animal models, bacterial hosts and types of administra-
tion (Table 2). Since in some cases only a transient
improvement has been reported, the use of phage
cocktails and multiple applications are recommended.
Of note, reports generally suggest that some phages
are naturally resistant to stomach conditions, at least to
the extent that allowed for the positive effects of treat-
ment (Bruttin and Brussow 2005; Litt and Jaroni 2017).
However, extreme pH of the stomach varies between
rodents (3.5–5.2) and humans (1.5) (Kararli 1995;
Fallingborg 1999; Beasley et al. 2015). Therefore, admin-
istration of phage with anti-acids (Koo et al. 2001), engi-
neered phages displaying lipids on their surfaces
(Nobrega et al. 2016) or microencapsulated phage for-
mulations (Ma et al. 2008; Islam et al. 2018) to increase
phage tolerance to acidity can be considered. It is also
important to highlight that phages offer the possibility
of reducing gut pathogens with a low impact on micro-
biota composition when compared with antibiotics
(Galtier et al. 2016).
In the future, more detailed phage-host interaction
studies in the gut should be further explored, testing
various dosages and schedules, and studies should be
extended to other gastrointestinal pathogens.
Specifically, Helicobacter pylori is a pathogen respon-
sible for acute gastritis and peptic ulcer diseases.
Despite being one of the most prevalent human patho-
gens, no lytic phages active on H. pylori have been iso-
lated so far. Furthermore, some well-known (e.g.
Shigella sonnei and Serratia marcescens) and newly iden-
tified bacterial species (e.g. Campylobacter concisus,
Edwardsiella tarda, Aeromonas hydrophila) should also
be considered as targets for phage control (Schlenker
and Surawicz 2009).
Urinary tract infections
Urinary tract infections (UTIs) are amongst the most
common bacterial infections, affecting annually around
150 million people worldwide (Stamm and Norrby
2001). It has been estimated that just in the US, 10 mil-
lion patients are admitted to hospital facilities with UTI
symptoms, causing health care costs of roughly US$3.5
billion annually (Foxman 2014). Such infections are
associated with morbidity in females (all ages), infant
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boys and older men (Flores-Mireles et al. 2015). UTIs are
infections affecting any part of the urinary tract, such as
the kidneys, ureters, bladder and urethra. These infec-
tions are usually caused by Enterobacteriaceae, namely
E. coli, K. pneumoniae and Proteus mirabilis (Flores-
Mireles et al. 2015).
There are a few studies regarding the efficacy of
phage therapy against UTIs. Escherichia coli is the main
causative agent of UTIs, and to control this type of
infections, Nishikawa et al. (2008) used phage therapy
on a mouse model. In that study, a lethal dose of an
uropathogenic E. coli strain was injected into the blad-
der. The authors observed that when phages were
injected into the peritoneal cavity, they were secreted
into the urine. The authors also observed that phage
efficacy in controlling the infections varied depending
on the phage strain and on the dose. The best results
were achieved with phage T4 at an MOI of 60, resulting
in survival of 100% of mice (Nishikawa et al. 2008).
Using a similar administration method, two phages
were used to combat Cronobacter turicensis UTI. This
cocktail reduced by 70% the bacterial burden on mice
kidneys. Moreover, other infection parameters were
reduced using phage therapy (Tothova et al. 2011).
The lack of in vivo studies in UTI-relevant models of
infection suggests that a lot of studies are still to be
performed, including those of dose effect, administra-
tion route, single phage versus phage cocktails, time of
administration, other locations of infection and other
pathogens. Nevertheless, the positive results described
so far are promising for the possible applications of
phage therapy against UTIs.
Bacteraemia
The presence of viable bacteria in the bloodstream is
called bacteraemia. If the host immune system fails to
eliminate bacteria from the blood, this results in sepsis
(Bone 1991). During recent years, the incidence of
either community- or hospital-acquired bacteraemia
has increased considerably (Friedman et al. 2002).
Bacteraemia aetiology varies according to geographic
location, environment, age, sex and physiological state
of the patient; mortality ranges from 4 to 41.5%
(Christaki and Giamarellos-Bourboulis 2014). Escherichia
coli, S. pneumoniae, MRSA, coagulase-negative staphylo-
cocci, and MDR enterococci are among the most fre-
quently isolated pathogens causing systemic infections
(Kollef et al. 2011) (Figure 1). The treatment of these
infections is difficult, mostly due to the spread of MDR
strains with a limited number of effective antibiotics
available. To overcome this problem, several studies
have been performed to assess the efficacy of phages
in the treatment of bacteraemia in different in vivo
models (Table 2).
The majority of studies have been based on models
of systemic infection in mice. Nevertheless, in 2009,
Heo et al. (2009) validated the use of a Drosophila mela-
nogaster model to evaluate the efficacy of phage ther-
apy. The systemic infection was caused by a lethal dose
of P. aeruginosa. Two phages administered by feeding
were able to significantly delay or prevent fly death.
Due to this positive effect, both phages were injected
into mice by either the i.m. or i.p. route 6 h after bacter-
ial challenge. A set of doses was studied. Although i.m.
administration showed better pharmacokinetics, i.p.
injection was more efficient in rescuing mice from
septicaemia caused by P. aeruginosa.
Tiwari et al. (2011) studied phage PA1Ø using differ-
ent MOIs (1, 10, and 100), injecting the phage i.p. into
both immunocompetent and neutropenic mice infected
with P. aeruginosa. While the phage therapy extended
the life time of neutropenic mice only for a short time,
normal mice were all rescued by phage treatment. The
authors also suggested that the combined effect of
phages and neutrophils was crucial for an efficient bac-
terial killing in the reported model (Tiwari et al. 2011).
However, in another study it was demonstrated that
phage therapy effectively controlled S. aureus infections
in neutropenic mice (Sunagar et al. 2010) and immuno-
suppression did not impair phage efficacy. A single
injection of GRCS phage in streptozotocin-induced dia-
betic mice was able to save 90% of the infected mice,
even when the treatment was delayed to 4 h after bac-
terial challenge.
Although the majority of the studies of phage ther-
apy relied on the use of a single phage, it was demon-
strated that a cocktail of three K. pneumoniae phages
injected i.p. had a stronger life-saving effect compared
to mono-phage therapy (Gu et al. 2012). This result was
attributed to the reduced mutation frequency of K.
pneumoniae during the cocktail treatment. Besides
reducing the level of bacterial counts in the blood-
stream and the consequent associated mortality,
phages were also able to alleviate gut microbiota
imbalance provoked by bacterial challenge (Cheng
et al. 2017).
Due to the rapid mortality caused by systemic infec-
tions, phage treatment has typically been applied
shortly after bacterial challenge. Almost all the models
recently reported relied on phage application up to 4 h
after bacterial inoculation (Pouillot et al. 2012). In a
lethal E. coli murine model, when a single dose of
phage particles was i.v. injected 10 and 60min
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following bacterial challenge, 100% and 95% mouse
survival was observed, respectively. However, no mice
were rescued when phage administration occurred 3 h
post-infection (Schneider et al. 2018). In contrast, one
report presented later use of phage therapy. In a rat
model of E. coli sepsis, EC200 phage was administered
7 h or 24 h after bacterial challenge and resulted in sur-
vival of 100% and 50% of rats, respectively (Pouillot
et al. 2012). It was recently suggested that the most
proper routes for phage delivery to combat bacter-
aemia are i.v., parenteral and transdermal administra-
tion (Oliveira et al. 2015), and for the majority of the
cited studies i.v. injections were successfully used to
combat systemic infections (Figure 1).
How pre-clinical studies in animal models
correspond to results of recent human tests
and clinical trials
Much of the knowledge of phage therapy practices is
derived from Eastern Europe, namely from Georgia and
Poland. At the Eliava Institute of Bacteriophages,
Microbiology and Virology in Georgia, the use of phage
cocktails is a standard medical practice used both for
preventing and controlling bacterial infections.
However, several studies are not well documented or
accessible in English (Kutter et al. 2010). In Poland, at
the Hirszfeld Institute of Immunology and Experimental
Therapy, historical and modern observations of the
potential of experimental phage therapy in humans are
documented (Miedzybrodzki et al. 2012). In the US and
Western Europe, only some studies have reached the
point of human testing under the standards of regula-
tory agencies. In the last 10 years, at least four phase I/II
clinical trials involving topical and oral phage adminis-
tration have been conducted. One of the first phase I
clinical trials, reported in 2009, was developed at the
Southwest Regional Wound Care Centre (USA) using a
phage cocktail targeting S. aureus, P. aeruginosa and E.
coli against venous leg ulcers, and aimed at assessing
the safety of phage therapy (Rhoads et al. 2009). In this
trial, no significant differences between test and control
groups were reported in terms of frequency of adverse
effects. Similar conclusions were taken from human vol-
unteers from Bangladesh administered with a T4-like
cocktail composed of nine phages (107 or 109 PFU
doses) or placebo (Sarker et al. 2012). In the random-
ized, double-blind, placebo-controlled study reported
by Wright et al. (2009), including 24 patients with
chronic otitis caused by P. aeruginosa, the efficacy of
the phage cocktail Biophage-PA was tested. The
authors reported statistically significant differences with
a decrease of the P. aeruginosa counts in phage-treated
patients, associated with an improvement of the clinical
indicators. Furthermore, no adverse effects were
reported. Encouraging results regarding the safety of
phage therapeutics are in line with those from animal
models, where adverse effects of phage treatments are
typically not observed.
More recently, the results of the phase I-II clinical
trial Phagoburn, which ran from 2015 to 2017 with the
objective to treat burn wounds infected with P. aerugi-
nosa, were reported (Jault et al. 2018). In this study, 27
patients were recruited, from which 13 were treated
with the phage cocktail with a predicted MOI of 10 and
14 with standard of care (1% sulfadiazine silver emul-
sion cream). The phage cocktail comprised 12 natural
lytic anti-P. aeruginosa phages and was administered
topically for 7 days. Although one participant of each
group died from treatment-unrelated reasons, generally
the phage cocktail was less efficient in reducing the
bacterial burden than standard of care. The authors
explained that these unsuccessful results were probably
due to the small patient sample size, the low phage
dose administered due to the loss of the titre of the ini-
tial phage preparation (during storage) and the low sus-
ceptibility of bacterial isolates to the low phage doses.
According to the authors, further studies addressing
these issues are needed (Jault et al. 2018). Of note, the
importance of phage dose for topical treatment of
infected wounds has been suggested by animal mod-
els, where the successful experiments reported MOIs
ranging between 10 and 200.
A placebo-controlled, double-blind trial has been
developed to investigate the efficacy of the phage
cocktail Pyo bacteriophage against UTIs in patients
planned for transurethral resection of the prostate. In
this trial, three groups of 27 patients have been
planned: (a) placebo solution; (b) Pyo bacteriophage
cocktail or; (c) antibiotic treatment. This trial was regis-
tered in 2017, and the outcomes of this study are still
awaited (Leitner et al. 2017). Finally, a phase II trial
(identifier code: NCT02664740) in progress aims to com-
pare the efficacy of standard treatment associated with
a topical anti-staphylococcal bacteriophage cocktail ver-
sus standard treatment plus placebo for diabetic foot
ulcers monoinfected by methicillin-resistant or suscep-
tible S. aureus (MRSA or MSSA) as measured by the rela-
tive reduction in wound surface area (%) at 12weeks.
No results from full-scale clinical trials involving intra-
venous phage administration have been reported so
far. Nevertheless, a few individual cases of compassion-
ate phage therapy have been documented. In 2017,
there were two cases where phage therapy was applied
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as last resort treatment to human patients. In a patient
with a P. aeruginosa-caused septicaemia, a cocktail of
two phages with activity against the patient’s strain
was administered. The cocktail was administered i.v.
every 6 h for 10 days and the patient’s wound was irri-
gated with the same cocktail every 8 h during the same
period. All infection parameters improved almost imme-
diately after the treatment (Jennes et al. 2017). In
another case report, nine phages were used to treat a
68-year-old diabetic patient with necrotising pancrea-
titis caused by a complicated MDR A. baumannii infec-
tion. Two different phage cocktails were developed,
one for i.v. administration and another for percutan-
eous administration into the abscess cavities. Eight days
after treatment, phage-resistant phenotypes of bacteria
emerged; thus a third cocktail for i.v. administration
was developed. After a few days of phage treatment,
the patient demonstrated improvement in all fronts
(Schooley et al. 2017). A few years before, in 2015
Fadlallah et al. (2015) reported a successful treatment
of a corneal infection caused by S. aureus at the Phage
Therapy Centre in Tbilisi. The patient was treated with
S. aureus phage SATA-8505 that was administered by
eye drops, nasal spray and i.v. for 4weeks. Six months
after treatment, the patient’s ocular signs stabilized and
no S. aureus was detected on ocular and nasal cultures.
This is in line with encouraging effects of phage ther-
apy in animal models of eye infections. More recently,
another successful clinical case was reported with the
administration of engineered phages for the treatment
of a patient with a disseminated drug-resistant
Mycobacterium abscessus infection. A significant
improvement of the overall clinical state was reported
after 32weeks of prolonged treatment with a three-
phage cocktail in multiple doses administered i.v. and
topically (Dedrick et al. 2019). On another recent study
case, three lung transplant recipients with life-threaten-
ing infections caused by P. aeruginosa (two patients)
and Burkholderia dolosa (one patient) received phage
therapy in combination with antibiotics. Cocktails com-
prising different lytic phages were selected for each
individual. Phages had different dosing routes and fre-
quencies, depending on cocktails and patients.
Although one of the patients died due to infection
relapsing, phage therapy was associated with a clinical
improvement of the patients not observed with anti-
biotic therapy (Aslam et al. 2019). Very recently another
successful case was reported involving phage and anti-
biotic combined therapy. A patient with a left tibial
infection caused by A. baumannii and K. pneumoniae
was treated with phages (i.v. injection) targeting both
strains along with meropenem and colistin. Few days
after treatment it was possible to observe tissue healing
and elimination of positive cultures. The treatment out-
come prevented patient’s leg from amputation (Nir-Paz
et al. 2019). The first obvious conclusion drawn from
these clinical studies and trials is that phage therapy
seems to be safe as no adverse effects were identified
in any of the reported studies. The same was concluded
from the pre-clinical studies in animal models. In terms
of its efficacy, the results are quite variable and very
dependent on the type of infection. Chronic infections
are generally more difficult to tackle than acute infec-
tions. These infections are characterized by the pres-
ence of biofilms, which are sessile bacteria in a low
metabolic state embedded in a self-produced polymeric
matrix that are difficult to access by potential antimicro-
bials, including phages (Pires et al. 2017). Chronic infec-
tions are also more difficult to mimic in animal models.
Nevertheless, both pre-clinical and clinical trials demon-
strated successful outcomes with topical application of
phages usually associated with prior debridement
(when it was possible) and using high phages titres.
Phage concentration seems to be a key factor for the
outcome of phage therapy, since in vivo trials demon-
strated better therapeutic efficacy when high phage
titres were applied, usually at an MOI of 10 and concen-
trations greater than 107 phage active particles per
treatment (107–109 PFU). The administration of a cock-
tail of phages has usually proven to be better than a
single phage application. Monophage therapy is prob-
ably more likely to lead to the emergence of phage
resistance in bacteria. It is also less likely that a random
clinical isolate of bacteria will be susceptible to one
phage (than to several); thus monotherapy probably
requires pre-testing for susceptibility of the infecting
bacteria to the phage, and sometimes in vitro and
in vivo susceptibilities do not coincide (Chibani-
Chennoufi et al. 2004). Other treatment variables such
as the optimal timing of administration, duration of
treatment and route of administration are difficult to
generalizse based on pre-clinical studies. For example,
treatment of systemic infections in mouse models only
proved to be effective when phages were administered
a short time after bacterial challenge (Gu et al. 2012).
Conversely, the few cases of compassionate treatment
of systemic infections in humans have been successful
independently of the timing of phage application.
However, in most clinical cases, patients are also receiv-
ing antibiotic therapy and therefore it is difficult to dis-
tinguish between the effect of phages and antibiotics
alone, or a potential synergistic effect. Although phage-
based clinical products are commercially available in
some Eastern European countries, in Western Europe or
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USA no phage products for clinical applications have
yet reached the commercial stage (Pelfrene et al. 2019).
In the future, the compilation of clinical trials data,
namely phase III results, will surely boost phage therapy
in Western medicine.
Challenges and limitations
The increasing amount and significance of phage ther-
apy studies over the last decades, and the promising
outcomes that have been achieved so far, have been
paving the way to bring phages into clinical practice.
Phages can play a vital role in the treatment of anti-
biotic-resistant infections, one of the greatest threats to
global health. Despite the great potential of phages,
there are still several constraints that limit their broad
application and acceptance in clinical practice. Some
issues can be an advantage or a disadvantage, such as
the limited phage host range, which allows for saving
commensal microbiota in treated patients but also
causes difficulties in rapid selection for an appropriate
phage to combat an infection. Furthermore, the emer-
gence of phage-insensitive bacterial mutants as well as
the relatively rapid clearance of phages by the immune
system may reduce phage efficacy in vivo. Also, the sta-
bility of various types of phages must be addressed in
the coming years of phage research (Loc-Carrillo and
Abedon 2011; Lu and Koeris 2011; Oliveira et al. 2015).
The problem of the narrow lytic spectra of phages is
often circumvented by the individual selection of
phages for each patient infected by specific bacteria, or
by the use of phage cocktail formulations, consisting in
the combination of multiple phages with complemen-
tary host ranges and features (e.g. targeting different
bacterial receptors) in a single preparation. Besides
expanding their spectrum of activity to target a wide
range of bacteria, phage cocktails also prevent the
emergence of phage-resistant variants (Chan et al.
2013). Another option consists of monitoring the bac-
terial population variation and applying consecutive
treatments with different phages effective against the
isolated infecting bacteria.
The choice of the administration dose and route has
a relevant impact on the outcome of treatment since its
efficacy is highly dependent on the phage concentra-
tion achieved at the site of infection (Malik et al. 2017).
Strategies to enhance the stability of phages in
unfavourable pHs or temperatures and to avoid phage
clearance from the body in order to maintain active
phages at infective doses are being explored. A possible
approach includes the encapsulation of phages on dif-
ferent matrices (e.g. in liposomes, alginate, cellulose
and others). In vivo studies using liposome-encapsu-
lated phages have reported better persistence of
phages at the infection site, increased stability and
enhanced therapeutic efficacies (Colom et al. 2015;
Chhibber et al. 2018). Such strategies are also important
to prolong shelf life during storage of phages. Most
phage preparations are used as liquid formulations and
the stability of these formulations is generally limited,
which is not a desirable feature for phages to become
regulated pharmaceuticals, where stable dosages and
well-defined pharmacokinetics and pharmacodynamics
are crucial (Vandenheuvel et al. 2015; Malik et al. 2017).
Another challenge concerning phage therapy is
safety in terms of phage preparations as they are
applied to patients. One reason is the presence of
endotoxins or other toxic bacterial products in crude
phage lysates that are released upon bacterial cell lysis
and that can trigger a harmful immune response.
Effective purification methods to remove bacterial con-
taminants from phage preparations are in high demand
for therapeutic phages (Van Belleghem et al. 2017).
Another issue is the fact that the majority of proteins
encoded in phage genomes do not have assigned func-
tions, which leaves practitioners with the unsolved
problem of predictions that may only go as far as the
current list of identified undesired genetic elements.
Moreover, many bacterial infections are related to the
development of bacterial biofilms, which are very diffi-
cult to treat as a consequence of the protective effect
of the exopolymeric matrix, which maintains the three-
dimensional biofilm structure, and the different meta-
bolic states of biofilm cells (Stewart and Franklin 2008).
Since it is very challenging to mimic real clinical bio-
films, most of the phage studies on biofilms have been
performed using in vitro or ex vivo models, and conse-
quently there is a lack of knowledge about how phages
interact with these bacterial communities. Therefore,
phage efficacy studies that investigate the interaction
of phages with bacterial cells under different metabolic
states are still required.
To enhance the antibacterial properties of phages
and to circumvent some of the limitations concerning
their application, several strategies have been
exploited. A possible approach is the combination of
phages with other antimicrobial agents, for example,
antibiotics, natural products, antiseptics or enzymes.
Besides the additive or synergistic effect that might
occur between them to enhance the bacterial killing,
this strategy could also arrest the proliferation of resist-
ant variants (Torres-Barcelo and Hochberg 2016).
Furthermore, the recent advances in the synthetic biol-
ogy field have opened a new window of opportunity to
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develop phage-engineering tools that can be applied
to build synthetic phages with novel and improved
functions. Several phage-engineering tools were devel-
oped and have been successfully applied to tailor
phage genomes in order to expand their host range,
improve their bactericidal efficacy and anti-biofilm
properties, reduce phage toxicity and immunogenicity,
revert bacterial resistance to antibiotics or enhance the
bactericidal activity of antibiotics (Hagens et al. 2004;
Lu and Collins 2007, 2009; Edgar et al. 2012; Pei and
Lamas-Samanamud 2014; Ando et al. 2015).
Concluding remarks
It is important to highlight that the phage therapy stud-
ies conducted in animal models are imperfect represen-
tations of the infections that occur in humans. For
instance, to demonstrate phage efficacy, lethal doses of
bacteria are typically administered to animals, which
results in rapid death, and the phage treatment is usu-
ally initiated immediately after bacterial challenge. Also,
there are no mouse strains with increased mucus clogs
in the airways and lungs that can have a significant
impact on phage effectiveness to control pathogens
associated with CF disorders. Also, the physiology of
animals is obviously different to that of humans, includ-
ing differences in anatomy, secretion (e.g. intestinal pH)
and microbiomes (Dabrowska 2019). Nevertheless,
while animal studies do not replicate human condition
perfectly, they are generally efficient and safe.
Moreover, the human clinical trials conducted so far
have reported no adverse effects concerning the use of
phages, which corresponds to observations in mice.
Despite all the advances in phage therapy and many
convincing examples of its efficacy, there are still many
challenges to overcome before phage therapy being
accepted in clinical practice. Clear guidelines need to
be put in place for the approval of both natural and
engineered phage-based products. This might encour-
age companies to invest in phage research, which is
currently limited.
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